Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis

Table 1 Main characteristics of all studies included in the meta-analysis

Study	District	Study period	Study size	Age (mean, years)	Gender (male/female)	Subgroups	Prognostic system	Follow-up time (mean, years)
Daniels [3]	Germany	2011	87	64.9	45/42	KIT/PDGFRA/BRAF/WT	NCCN risk	NA
Taniguchi [14]	Japan	1999	124	60	NA	KIT positive/negative	BM	4.1
Sakurai [15]	Japan	1999	48	59.4	21/27	KIT positive/negative	BM	3.7
Yamamoto [16]	Japan	2004	27	59	15/24	KIT/PDGFRA/WT	M-MIB index	3.6
Lin [17]	Taiwan	2006	25	63.2	13/12	KIT positive/negative	NA	NA
Kim [18]	Korea	2004	86	59.5	47/39	KIT positive/negative	NIH risk	NA
Liu [19]	China	2005	82	53	56/26	KIT positive/negative	BM	4.1
Tzen [20]	Taiwan	2007	134	NA	74/60	KIT/PDGFRA/WT	NA	3.9
Cho [21]	Japan	2006	56	61	35/21	KIT/PDGFRA/WT	BM	4.7
Keun [22]	Korea	2008	68	56	31/37	KIT/PDGFRA/WT	NIH risk	5.0
Andersson [23]	Sweden	2006	177	NA	NA	KIT/PDGFRA/WT	MTR-KI67 index	6.2
Haller [24]	Germany	2005	38	64	22/16	KIT/PDGFRA/WT	NIH risk	2.7
Steigen [25]	Norway	2007	89	64.8	50/39	KIT/PDGFRA/WT	BM	NA
Zheng [26]	China	2011	25	58	15/10	KIT/PDGFRA/WT	MC-KI67 index	3.2
Wardelmann [27]	Germany	2003	55	62	29/26	KIT/PDGFRA/WT	BM	NA
Martín [28]	Spain	2005	162	63	82/80	KIT positive/negative	NIH risk	3.5
Penzel [29]	Germany	2005	79	60.9	41/38	KIT/PDGFRA/WT	NIH risk	NA
Agaram [30]	America	2006	125	NA	NA	KIT/PDGFRA/WT	NA	NA

BM, benign to malignant; NA, not available; NCCN, National Comprehensive Cancer Network; NIH, National Institutes of Health; MC-KI67 index, mitotic count and Ki-67 index; M-MIB index, mitotic rate and MIB-1 index; MTR-KI67 index, maximum tumor size and Ki67 index; WT, wild type.

ISSN: 1477-7819